Unknown

Dataset Information

0

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.


ABSTRACT: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic. Here, we explore the KIT-inhibitory activity of ponatinib in preclinical models and describe initial characterization of its activity in patients with GIST.The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines. The ponatinib-KIT costructure was also determined. The clinical activity of ponatinib was examined in three patients with GIST previously treated with all three FDA-approved agents.In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop. Ponatinib also induced regression in engineered and GIST-derived tumor models containing these secondary mutations. In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L. This inhibitory profile could be rationalized on the basis of structural analyses. Ponatinib (30 mg daily) displayed encouraging clinical activity in two of three patients with GIST.Ponatinib possesses potent activity against most major clinically relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST. These data strongly support further evaluation of ponatinib in patients with GIST.

SUBMITTER: Garner AP 

PROVIDER: S-EPMC4233175 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Garner Andrew P AP   Gozgit Joseph M JM   Anjum Rana R   Vodala Sadanand S   Schrock Alexa A   Zhou Tianjun T   Serrano Cesar C   Eilers Grant G   Zhu Meijun M   Ketzer Julia J   Wardwell Scott S   Ning Yaoyu Y   Song Youngchul Y   Kohlmann Anna A   Wang Frank F   Clackson Tim T   Heinrich Michael C MC   Fletcher Jonathan A JA   Bauer Sebastian S   Rivera Victor M VM  

Clinical cancer research : an official journal of the American Association for Cancer Research 20140919 22


<h4>Purpose</h4>KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic. Here, we explore the KIT-inhibitory activity of ponatinib in preclinical models and describe initial characterization of its activity in patients w  ...[more]

Similar Datasets

| S-EPMC3708046 | biostudies-literature
| S-EPMC3859154 | biostudies-other
| S-EPMC3405472 | biostudies-literature
| S-EPMC4118194 | biostudies-literature
| S-EPMC5361605 | biostudies-literature